Evidence map›Paper›PMID 35562168›Full record

ArticleBritish journal of clinical pharmacology2022

Skeletal muscle relaxant drug-drug-drug interactions and unintentional traumatic injury: Screening to detect three-way drug interaction signals.

Cheng Chen, Sean Hennessy, Colleen M Brensinger, Ghadeer K Dawwas, Emily K Acton, Warren B Bilker, Sophie P Chung, Sascha Dublin, John R Horn, Todd A Miano and 3 more

Abstract read
In one paragraph

Article in British journal of clinical pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Cheng ChenCenter for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0002-3240-8153
Sean HennessyCenter for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, United States.
Colleen M BrensingerCenter for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, United States.
Ghadeer K DawwasCenter for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, United States.
Emily K ActonCenter for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, United States.
Warren B BilkerCenter for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, United States.
Sophie P ChungAthenaHealth, Inc, Watertown, MA, United States.
Sascha DublinKaiser Permanente Washington Health Research Institute, Seattle, WA, United States.
John R HornDepartment of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, United States.
Todd A MianoCenter for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0002-3832-6212
Thanh Phuong Pham NguyenCenter for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, United States.
Samantha E SopranoCenter for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, United States.
Charles E LeonardCenter for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, United States.

Funding

Clinical Importance of Drug-Drug InteractionsR01AG025152 · NIA · UNIVERSITY OF PENNSYLVANIA · PI HENNESSY, SEAN, LI, LANG · 2006 to 2021
$8.1M
Drug interactions involving psychoactive drugsR01AG060975 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Charles Edward Leonard · 2019 to 2026
$3.9M
Drug-Drug Interactions Involving Methadone and BuprenorphineR01DA048001 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI HENNESSY, SEAN · 2019 to 2023
$2.9M
Enhancing the Utility of the Trend-in-Trend Research DesignR01AG064589 · NIA · UNIVERSITY OF PENNSYLVANIA · PI HENNESSY, SEAN, SMALL, DYLAN S · 2019 to 2022
$2.2M
NIA NIH HHS R01 AG025152NIA NIH HHS R01 AG060975NIA NIH HHS R01 AG064589NIDA NIH HHS R01 DA048001
6 · The paper itself

Abstract

aimThe aim of this study was to identify skeletal muscle relaxant (SMR) drug-drug-drug interaction (3DI) signals associated with increased rates of unintentional traumatic injury.

methodsWe conducted automated high-throughput pharmacoepidemiologic screening of 2000-2019 healthcare data for members of United States commercial and Medicare Advantage health plans. We performed a self-controlled case series study for each drug triad consisting of an SMR base-pair (i.e., concomitant use of an SMR with another medication), and a co-dispensed medication (i.e., candidate interacting precipitant) taken during ongoing use of the base-pair. We included patients aged ≥16 years with an injury occurring during base-pair-exposed observation time. We used conditional Poisson regression to calculate adjusted rate ratios (RRs) with 95% confidence intervals (CIs) for injury with each SMR base-pair + candidate interacting precipitant (i.e., triad) versus the SMR-containing base-pair alone.

resultsAmong 58 478 triads, 29 were significantly positively associated with injury; confounder-adjusted RRs ranged from 1.39 (95% CI = 1.01-1.91) for tizanidine + omeprazole with gabapentin to 2.23 (95% CI = 1.02-4.87) for tizanidine + diclofenac with alprazolam. Most identified 3DI signals are new and have not been formally investigated.

conclusionWe identified 29 SMR 3DI signals associated with increased rates of injury. Future aetiologic studies should confirm or refute these SMR 3DI signals.

Indexed as

AlprazolamNeuromuscular AgentsAgedDiclofenacDrug InteractionsGabapentinHumansMedicareOmeprazoleUnited StatesAlprazolamDiclofenacGabapentinNeuromuscular AgentsOmeprazoledrug interactionsinjurymuscle relaxantspharmacoepidemiologypopulation healthself-controlled case series

Identifiers

PMID35562168
PMCPMC9560998

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.